Last reviewed 2026-04-19 · How we verify

aH5N8c on Day 1

Seqirus · Phase 2 active Biologic

aH5N8c on Day 1 is a Biologic drug developed by Seqirus. It is currently in Phase 2 development.

At a glance

Generic name	aH5N8c on Day 1
Sponsor	Seqirus
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

aH5N8c on Day 1 CI brief — competitive landscape report
aH5N8c on Day 1 updates RSS · CI watch RSS
Seqirus portfolio CI

Frequently asked questions about aH5N8c on Day 1

What is aH5N8c on Day 1?

aH5N8c on Day 1 is a Biologic drug developed by Seqirus.

Who makes aH5N8c on Day 1?

aH5N8c on Day 1 is developed by Seqirus (see full Seqirus pipeline at /company/seqirus).

What development phase is aH5N8c on Day 1 in?

aH5N8c on Day 1 is in Phase 2.

Manufacturer: Seqirus — full pipeline
Compare: aH5N8c on Day 1 vs similar drugs
Pricing: aH5N8c on Day 1 cost, discount & access